Rimassa, LorenzaLorenzaRimassaKelley, Robin KateRobin KateKelleyMeyer, TimTimMeyerRyoo, Baek-YeolBaek-YeolRyooMerle, PhilippePhilippeMerlePark, Joong-WonJoong-WonParkBlanc, Jean-FredericJean-FredericBlancLim, Ho YeongHo YeongLimTran, AlbertAlbertTranChan, Yi-WahYi-WahChanMcAdam, PaulPaulMcAdamWang, EvelynEvelynWangANN-LII CHENGEl-Khoueiry, Anthony BAnthony BEl-KhoueiryAbou-Alfa, Ghassan KGhassan KAbou-Alfa2023-01-122023-01-122022-012235-1795https://scholars.lib.ntu.edu.tw/handle/123456789/627195Cabozantinib, an inhibitor of MET, AXL, and VEGF receptors, significantly improved overall survival (OS) and progression-free survival (PFS) versus placebo in patients with previously treated advanced hepatocellular carcinoma (HCC). In this exploratory analysis, outcomes were evaluated according to plasma biomarker levels.enCabozantinib; Hepatocellular carcinoma; Plasma biomarkers; Prognostic factors[SDGs]SDG3Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinomajournal article10.1159/000519867352225062-s2.0-85121125776WOS:000729156900001https://api.elsevier.com/content/abstract/scopus_id/85121125776